Effect of ABCB1 C3435T Polymorphism on Creatinine levels in Kenyan HIV Patients on Lopinavir-Based Regimens

Abstract

Abstract

ATP Binding Cassette sub-family B member 1 (ABCB1) affects disposition of many drugs and thus affects the pharmacokinetics of drugs and ultimately treatment response. Polymorphisms of ABCB1 especially ABCB1 C3435T polymorphism may affect excretion of lopinavir and eventually the pharmacokinetics of lopinavir.

Methods:

The study design was a historical cohort study and entailed collection of patient data. PureLink® genomic DNA extraction mini kit was used for the extraction and purification of genomic DNA. TaqMan® drug genotyping assay and protocol was used in the DNA amplification and genotyping. Data analysis was done using STATA software version 10.

Results:

Study participants with the ABCB1 3435 CT genotype had lower creatinine levels after 6 months on lopinavir-based regimens compared with those with the CC genotype (p = 0.001). However, there was no significant association between the ABCB1 C3435T genotypes and creatinine levels at baseline and at the time of switching therapy from first line antiretroviral therapy to second-line antiretroviral therapy which was lopinavir-based.

Conclusion:

ABCB1 C3435T polymorphism affects creatinine levels 6 months after therapy on lopinavir-based regimens.